Management ChangeMay 12, 2026, 04:37 PM
NEXGEL Appoints Brian Kieser & Kevin Harris to Board
AI Summary
NEXGEL, Inc. announced the appointment of Brian J. Kieser and Kevin M. Harris to its Board of Directors on May 6, 2026. Both appointees are executives at Sequence LifeScience, which recently led a $5.5 million strategic investment to finance NEXGEL's acquisition of assets and licenses from Celularity Inc. Additionally, Mr. Kieser made a personal investment of $1 million in NEXGEL through a convertible promissory note and warrant.
Key Highlights
- Brian J. Kieser and Kevin M. Harris appointed to NEXGEL's Board of Directors on May 6, 2026.
- Mr. Kieser is CEO and Mr. Harris is COO of Sequence LifeScience.
- Sequence LifeScience led a $5.5 million strategic investment in NEXGEL.
- The investment supported NEXGEL's acquisition of certain assets and licenses from Celularity Inc.
- Mr. Kieser personally invested $1 million in NEXGEL via a convertible promissory note and warrant.
- Convertible notes have an initial conversion price of $0.60 per share.
- Warrants are exercisable at an initial price of $0.80 per share.
Price Impact
More from NXGL